gener pharma thought near-term posit
confer takeaway thought set-up teva
return gener industri confer buy/sell-sid present caught
industri contact meet coincid pick-up investor focu around set-up
upcom earn season kick thur remaind report next week overal tone
repres on-going challeng reflect industri litig sieg opioid
price fix industri dynam continu present challeng buyer increasingli split
suppli relationship aggress rebat name look see select pressur
out-year ebitda teva expect opioid headlin continu drive stock
perform teva op-rat stock realiti close
still month away investor seemingli put stock show-m box
larger manufactur still trade ebitda rang would focus downsid
revis out-year ebitda risk stock downsid given leverage/cash flow focu
thought set-up order convict also lower teva target
report call dial-in expect see full year ebitda
rang million lower street-low lot move part
drill separ note last night link realiti new launch biggest
driver light consensu slow move remain million
believ buysid million million also question
street ebitda step-up million million
teva report call dial-in id lower out-year
ebitda target last night see separ note link actual full year set-up
benign line quarter billion ebitda lack surpris buysid also
concern street out-year forecast cut gross margin oper
expens assumpt us biggest risk outsid opioid headlin
report call et dial-in id like consensu
bar head thur ebitda step million million
quarter walk detail note mon link debt refinanc
manufactur progress also high focu list
report call et dial-in id slightli
consensu ep focu versu hold strong view quarter
think import updat come tomorrow result upjohn/china call
trepid remain biggest factor weigh sentiment share impli newco
pro-forma valuat ev/ebitda low expect leav attract set-up
patienc
report call et dial-in id expect anoth
quarter earn stabil remain overshadow opioid-driven volatil slightli
street ebitda million versu million within guidanc rang
cch remain focu await bla accept fda bla file within
accept window opioid headlin continu drive stock volatil
follow last minut mdl track one settlement trial expect
settlement talks/headlin like continu
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
gener pharma thought near-term posit
analyst respons prepar research report receiv compens base upon variou factor includ
total revenu member compani capit market affili portion gener
invest bank activ member compani capit market affili
pleas note current conflict disclosur may differ public date set forth
report access current conflict disclosur client refer http //www rbccm com/gldisclosure/publicweb/
send request cm research publish bay street royal bank plaza
capit market llc make market secur inc
capit market llc make market secur inc
member compani capit market one affili manag co-manag public offer secur endo
plc past month
member compani capit market one affili receiv compens invest bank servic
plc past month
capit market llc make market secur plc
dominion secur inc make market secur plc
member compani capit market one affili receiv compens product servic
invest bank servic plc past month time member compani
capit market one affili provid non-secur servic plc
capit market current provid plc non-secur servic
capit market provid plc invest bank servic past month
capit market llc make market secur
capit market llc make market secur teva pharmaceut industri limit
member compani capit market one affili receiv compens product servic
invest bank servic teva pharmaceut industri limit past month time member
compani capit market one affili provid non-secur servic teva pharmaceut industri limit
capit market current provid teva pharmaceut industri limit non-secur servic
explan capit market equiti rate system
analyst sector univers compani analyst provid research coverag accordingli rate assign
particular stock repres sole analyst view stock perform next month rel
top pick tp repres analyst best idea sector expect provid signific absolut total return month
favor risk-reward ratio
outperform expect materi outperform sector averag month
sector perform sp return expect line sector averag month
under-perform return expect materi sector averag month
gener pharma thought near-term posit
restrict polici preclud certain type commun includ invest recommend
act advisor certain merger strateg transact certain circumst
rate nr rate price target estim remov due applic legal regulatori polici constraint
may includ capit market act advisori capac involv compani
specul risk rate reflect secur lower level financi oper predict illiquid share trade volum
high balanc sheet leverag limit oper histori result higher expect financi and/or stock price volatil
distribut rate
purpos rate distribut regulatori rule requir member firm assign rate one three rate categori
 buy hold/neutr sell regardless firm rate categori although capit market rate top pick/
outperform sector perform under-perform close correspond buy hold/neutr sell respect mean
rate determin rel basi
distribut rate
rate price target histori inc us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
gener pharma thought near-term posit
rate price target histori inc us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori plc us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
gener pharma thought near-term posit
rate price target histori mylan us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
rate price target histori teva pharmaceut industri limit teva us usd
tp top pick outperform sp sector perform under-perform restrict initi research coverag discontinu research coverag
nr rate na avail rl recommend list rl refer date secur place recommend list rl refer date
secur remov recommend list rtg rate
creat bluematrix
refer recommend list recommend histori chart may includ one recommend list model
portfolio maintain wealth manag one affili wealth manag recommend list includ
guid portfolio prime incom rl guid portfolio dividend growth rl guid portfolio adr rl
guid portfolio cap growth rl capit market recommend list includ strategi focu list
fundament equiti weight portfolio abbrevi rl mean date secur place
recommend list abbrevi rl mean date secur remov recommend list
equiti valuat risk
valuat method use determin risk may imped achiev price target cover compani pleas
see recent company-specif research report http //www rbcinsightresearch com send request capit
gener pharma thought near-term posit
price target base equal ep ebitda estim balanc blend captur
higher leverag given declin ebitda greater earn growth reset base given magnitud risk uncertainti
involv believ price target impli return support sector perform specul risk rate specul risk
qualifi reflect volatil given on-going oper strateg turnaround
risk rate price target
two major risk outlook worsen manufactur issu decatur somerset facil
 deterior higher spend and/or inabl convert pipelin
price target base equal price-to-earnings ev/ebitda multipl appli estim use target multipl
respect result gener valuat framework taken trough price-to-earnings valuat
histor averag ev/ebitda valuat made adjust base company-specif attribut ev/ebitda
incorpor opioid liabil estim within capit structur impli return price target support sector
risk rate price target
risk price target rate includ eros base busi compar assumpt challeng drive
growth brand busi delay launch pipelin opportun
price target base equal price-to-earnings ev/ebitda use target multipl respect
result gener valuat framework taken trough price-to-earnings valuat histor averag
valuat made adjust base company-specif attribut ev/ebitda incorpor opioid liabil estim
within capit structur impli return price target support sector perform rate
risk rate price target
risk rate price target aris greater-than-expect competit key product continu eros
base busi approv pend anda opportun grow ebitda convert free
cash flow given high leverag pend cash call includ mesh litig
price target base ev/ebitda multipl appli pro-forma newco ebitda estim
modestli valuat level trade pre-deal announc sector histor averag multipl
reflect continu challeng industri impli return price target opportun upsid
support outperform rate
risk rate price target
risk rate price target includ limit delay around pipelin convers slower expect
new launch uptak impair us base busi delay upjohn deal close and/or integr issu
inopportun use cash boost leverag and/or impair sharehold valu
gener pharma thought near-term posit
price target base equal price-to-earnings ev/ebitda reflect teva moder lower tax rate current leverag
price target base multipl respect result gener valuat framework
reflect uniqu fundament risk current environ particularli around opioid uncertainti ii uncertainti
around addit gener copaxon launch iii brand pipelin without risk iv leverag risk heighten
risk rate price target
follow could lead teva realiz downsid price target rate slower expect sale ramp
ajovi austedo higher expect top-lin impact base busi aggress cost cut continu price
pressur multipl addit gener copaxon launch weak cash flow gener jeopard debt paydown
coven complianc uncertainti around potenti liabil associ opioid litig
capit market polici manag conflict interest relat invest research avail us request
access current polici client refer
send request capit market research publish bay street royal bank plaza floor south
tower toronto ontario reserv right amend supplement polici time
dissemin research short-term trade idea
capit market endeavor make reason effort provid research simultan elig client
regard local time zone oversea jurisdict capit market equiti research post proprietari websit
ensur elig client receiv coverag initi chang rate target opinion time manner addit
distribut may done sale personnel via email fax electron mean regular mail client may also
receiv research via third parti vendor capit market also provid elig client access sparc firm
proprietari insight websit via email via third-parti vendor sparc contain market color commentari regard
subject compani firm current provid equiti research coverag research analyst may time time
includ short-term trade idea research report sparc short-term trade idea offer short-term view
secur may trade base market trade event result trade opportun may avail
short-term trade idea may differ price target recommend publish research report reflect
research analyst view long-term one year prospect subject compani result differ time horizon
methodolog and/or factor thu possibl subject compani common equiti consid long-term
sector perform even under-perform might present short-term buy opportun result temporari sell pressur
market convers subject compani common equiti rate long-term outperform could consid suscept
short-term downward price correct short-term trade idea rate part rate system
firm gener intend undertak oblig maintain updat short-term trade idea short-term trade
idea may suitabl investor tailor individu investor circumst object
investor make independ decis regard secur strategi discuss herein pleas contact
invest advisor institut salesperson inform regard capit market research
list recommend compani dissemin prior period pleas click
month histori sparc view http //www rbcinsightresearch com
view express report accur reflect person view respons analyst
subject secur issuer part compens respons analyst name herein directli
indirectli relat specif recommend view express respons analyst report
gener pharma thought near-term posit
global industri classif standard gic develop exclus properti servic mark inc standard poor financi servic
llc licens use neither parti involv make compil gic gic classif make express impli
warranti represent respect standard classif result obtain use thereof parti herebi expressli disclaim warranti
origin accuraci complet merchant fit particular purpos respect standard classif without limit forego
event shall affili third parti involv make compil gic gic classif liabil direct indirect special
punit consequenti damag includ lost profit even notifi possibl damag
refer herein libor libo rate libor abbrevi mean london interbank offer rate administ benchmark administr
person take administr rate
capit market busi name use certain branch subsidiari royal bank canada includ dominion secur inc
capit market llc europ limit royal bank canada hong kong branch royal bank canada sydney branch inform contain
report compil capit market sourc believ reliabl represent warranti express impli made royal
canada capit market affili person accuraci complet correct opinion estim contain
report constitut capit market judgement date report subject chang without notic provid good faith without
legal respons noth report constitut legal account tax advic individu tailor invest advic materi prepar gener
circul client prepar without regard individu financi circumst object person receiv invest
servic contain report may suitabl recommend consult independ invest advisor doubt
suitabl invest servic report offer sell solicit offer buy secur past perform guid
futur perform futur return guarante loss origin capit may occur capit market research analyst compens base
part overal profit capit market includ profit attribut invest bank revenu everi provinc canada state
 countri throughout world law regul type secur invest product may offer
resid well process result secur discuss report may elig sale jurisdict capit
market may restrict publish research report time time due regulatori restrict and/ intern complianc polici case
latest publish research report avail client may reflect recent materi chang applic industri and/or applic subject compani
capit market research report current date set forth research report report circumst
constru solicit act secur broker dealer jurisdict person compani legal permit carri busi
secur broker dealer jurisdict full extent permit law neither capit market affili person accept
liabil whatsoev direct indirect consequenti loss aris connect use report inform contain herein
matter contain document may reproduc copi mean without prior written consent capit market instanc
addit inform avail request
public approv capit market llc member finra nyse sipc regist broker-deal accept
respons report dissemin unit state recipi report regist broker-deal bank act
broker dealer capac wish inform regard effect transact secur discuss report
contact place order capit market llc
public approv dominion secur inc member iiroc canadian recipi report design institut
ontario accredit investor british columbia alberta sophist purchas quebec similar permit purchas provinc
wish inform regard effect transact secur discuss report contact place order
dominion secur inc without way limit forego accept respons report dissemin canada
public approv europ limit el author prudenti regul author regul
conduct author fca prudenti regul author connect distribut unit kingdom materi gener
distribut unit kingdom retail client defin rule fca rbcel accept respons report dissemin
unit kingdom
materi distribut germani europ limit frankfurt branch regul bundesanstalt fr finanzdienstleistungsaufsicht bafin
receiv advic australia
materi distribut australia royal bank canada sydney branch abn afsl materi prepar
gener circul take account object financi situat need recipi accordingli recipi act
materi consid appropri materi regard object financi situat need materi relat acquisit
possibl acquisit particular financi product recipi australia obtain relev disclosur document prepar respect product
